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stents (DES) have drastically reduced the incidence of ISR, treatment of DES-ISR is particularly challenging. ISR
mainly results from aggressive neointimal proliferation, but recent data also suggest that neoatherosclerosis may
play an important pathophysiological role. Intracoronary imaging provides unique insights to unravel the underlying
substrate of ISR and may be used to guide repeated interventions. In this paper, we systematically reviewed clinical
trial data with currently available therapeutic modalities, including DES and drug-coated balloons, in patients
presenting with ISR within bare-metal stents or DES. (J Am Coll Cardiol 2014;63:2659–73)ª 2014 by the American
College of Cardiology FoundationTreatment of patients with in-stent restenosis (ISR) remains
a challenge (1). Bare-metal stents (BMS) are still frequently
used during percutaneous coronary intervention, although
they are associated with relatively high restenosis rates,
especially when used in complex clinical and anatomic sce-
narios (2). Factors associated with the current use of BMS
include the unaffordable price of drug-eluting stents (DES)
in certain geographic areas, concerns about a high risk of
bleeding in relation to a requirement for prolonged dual
antiplatelet therapy after DES, and a perceived low reste-
nosis risk in large coronary vessels. Accordingly, treatment of
patients with BMS-ISR continues to represent a signiﬁcant
therapeutic burden in routine clinical practice in many
catheterization laboratories around the world (1,2).
The introduction of DES has drastically reduced the
occurrence of severe neointimal proliferation, the dominant
cause of restenosis after stent implantation (3). This decrease
translated into important reductions in clinical need for
subsequent repeat revascularization (4,5). However, ﬁrst-
generation DES were plagued by safety concerns related to
a small, but clinically relevant, increase in the risk of very-late
stent thrombosis (6). Recently, however, the adoption of
newer-generation DES and their unrestricted use in clinical
practice has proven that these devices are not only more
effective (7) but also safer (8,9) compared with ﬁrst-
generation DES. Nevertheless, DES are not immune to
restenosis. In fact, routine angiographic surveillance afterc Department, Hospital Universitario de La Princesa Madrid,
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bruary 11, 2014.unrestricted use of newer-generation devices demonstrates
rates of angiographic restenosis of approximately 12% (7).
Of additional concern, the treatment of patients with DES-
ISR has proven to be particularly challenging (1,10).
In the present review, we discuss currently available
therapeutic strategies for the management of patients with
ISR. We performed a systematic review to identify all ran-
domized clinical trials published on this subject (11–39).
Results of the most recent trials, especially those assessing
novel modalities, are critically discussed in the light of pre-
vious evidence. In addition, we review recent developments
relating to delineation of the underlying substrate accounting
for late stent failure. Notably, recent pathological studies
demonstrated that “neoatherosclerosis” represents a common
substrate in patients with late stent failure (40). In this re-
gard, progress in intracoronary imaging techniques was able
to unravel the underlying pathological substrate of ISR
in vivo (1). This information may be used to select and tailor
interventions to tackle the underlying putative mechanisms
and also to optimize results of these repeated interventions.
Methods
A search in MEDLINE, Embase, and the Cochrane Central
Register of Controlled Trials was performed (without lan-
guage restrictions) from 1995 through November 30, 2013.
In addition, abstract lists and conference proceedings from
the 2013 scientiﬁc meetings of the American College of
Cardiology, the European Society of Cardiology, Trans-
catheter Cardiovascular Therapeutics, the American Heart
Association, and the World Congress on Cardiology were
searched. We used, as search limits, the following: humans,
randomized controlled trial, “coronary restenosis” and “in-
stent restenosis” (Medical Subject Headings). Reference lists
from these papers were also reviewed for additional studies.
Abbreviations
and Acronyms
BA = balloon angioplasty
BMS = bare-metal stent(s)
DCB = drug-coated
balloon(s)
DES = drug-eluting stent(s)
ISR = in-stent restenosis
OCT = optical coherence
tomography
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2660Only randomized clinical trials
comparing therapeutic modalities
in patients with ISR were in-
cluded (29 randomized studies in
total [11–39]).Relevant Clinical and
Anatomic Issues
Deﬁnition. The deﬁnition of ISR
remains an angiographic one:
namely, recurrent diameter ste-nosis >50% at the stent segment or its edges (5-mm seg-
ments adjacent to the stent) (41,42). Angiography not only
allows determination of ISR severity but also its morpho-
logical pattern. The Mehran system permits a morpho-
logical classiﬁcation of BMS-ISR lesions (pattern I, focal;
pattern II, diffuse; pattern III, proliferative; and pattern
IV, occlusion) and can predict the need for repeat revas-
cularization after intervention (19%, 35%, 50%, and 98%,
respectively) (42). This classiﬁcation scheme also has
prognostic value in patients with DES-ISR (43). In addi-
tion, the American College of Cardiology/American
Heart Association classiﬁcation has been validated in pa-
tients with ISR: B2-C lesions are not only more frequently
associated with suboptimal acute results, but also with
a higher restenosis rate and poorer long-term clinical
outcomes (44).
Clinical presentation. In terms of clinical presentation,
ISR had traditionally been thought to represent a relatively
benign clinical entity, with predominantly stable clinical
presentation and largely satisfactory acute results with repeat
interventions (1,45). This was in keeping with the prevailing
etiologic paradigm suggesting that the progressive homo-
geneous smooth muscle cell proliferation constituted the
universal substrate of ISR. More recent studies, however,
suggest that patients with ISR frequently present with un-
stable symptoms and, in fact, many of them exhibit eleva-
tions of cardiac markers fulﬁlling diagnostic criteria for
myocardial infarction (7,46).
Whether acute coronary syndrome presentations are
more common with DES-ISR remains unknown. How-
ever, a shift in the underlying pathological substrate toward
restenotic lesions with a higher proportion of in-stent
atherosclerotic plaque, the so-called neoatherosclerosis
(40), means that this hypothesis deserves further investi-
gation (Fig. 1). Conversely, the natural history of “asymp-
tomatic” patients with angiographic restenosis seems
favorable (47). Therefore, treatment of asymptomatic pa-
tients (the so-called “oculostenotic reﬂex”) should be avoi-
ded whenever possible (48,49). In some cases, however,
very severe ISR (>75% diameter stenosis according to
quantitative coronary angiography) has also been considered
a clinical indication for repeat revascularization. Currently,
the functional signiﬁcance of ISR may be readily evaluated
in the catheterization laboratory by using the pressure wire,and prospective studies have validated the use of fractional
ﬂow reserve for clinical decision making in these patients
(50). Notably, the clinical outcome of patients with ISR
with deferred interventions based on a fractional ﬂow
reserve >0.75 is excellent (51). This diagnostic strategy is
especially attractive in patients with angiographically mod-
erate or ambiguous ISR.
Type of underlying stent: BMS-ISR versus DES-ISR.
Accumulating evidence strongly suggests that there are
signiﬁcant differences between ISR that occur after BMS
compared with those seen after DES (1,10,52). Time of
presentation, morphological patterns, underlying substrate,
and response to interventions largely differ in patients with
BMS-ISR and DES-ISR (1,52). This ﬁnding is consistent
with observations that the time course of neointimal accu-
mulation differs considerably after DES compared with after
BMS (53,54), which reﬂects a manifestation of delayed
arterial healing that seems to characterize the vascular
response after DES implantation (55). Moreover, compared
with BMS-ISR, DES-ISR tends to exhibit a focal pattern,
often affecting the stent edges. This outcome may be
because the overall high suppression of neointimal growth by
DES means that technical problems, including geographic
miss phenomenon or strut fractures, are relatively more
important contributing factors in patients with DES-ISR
(1,45). In addition, neoatherosclerosis occurs not only
more frequently, but also earlier in patients with DES-ISR
compared with those with BMS-ISR (40) (Table 1).
Underlying substrate. Assessing the main underlying cause
of ISR may be critical for guidance and optimization of these
repeated interventions (1,45). In many patients, underlying
mechanical problems explain the subsequent development of
ISR. These tend to be preventable and, more importantly, if
adequately recognized, they may be corrected during rein-
terventions. Underexpansion is considered a major factor
triggering ISR after either BMS or DES implantation
(56,57). This problem may be due to stent underdeployment
as a result of undersizing or due to the use of low deploy-
ment pressures (57). Conversely, resistant underexpansion
may be caused by the presence of underlying heavily calciﬁed
lesions that prevent adequate stent expansion despite high
dilation pressures. In other patients, however, ISR is
detected in well-expanded stents. In selected patients, stent
misplacement or stents not fully covering the underlying
lesion may explain the appearance of focal ISR. “Candy
wrapper” angiographic appearance is typical of geographic
miss, particularly in patients treated with DES or brachy-
therapy (58). In this scenario, the sharp contrast between the
excellent appearance in the stent lumen (effective suppres-
sion of neointimal growth) and the focal-edge restenosis
(negative remodeling, plaque growth, or both) accounts for
this distinctive angiographic pattern.
Stent fractures may also trigger focal ISR or even stent
thrombosis. Fractures are more frequent in the right coro-
nary artery and occur more frequently in some DES types
(1,59). Repeat stent implantation is frequently advocated
Figure 1 Pathological Images of In-Stent Restenosis
Low-power (A and B, 4) and high-power (C and D, 10) magniﬁcation images of restenosis within (A and C) a bare-metal stent (BMS) and (B and D) a drug-eluting stent (DES),
both implanted 5 years antemortem. In the BMS, the dominant pathology is smooth muscle cell-rich neointimal hyperplasia. There is also some chronic inﬂammation with
neovascularization around stent struts (green arrowhead). In the DES, there is presence of neoatherosclerosis with formation of a necrotic core (black arrowheads) and
calciﬁcation (grey arrowheads). Courtesy of Dr. Michael Joner, CVPath Inc., Gaithersburg, Maryland.
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2661in this setting. Finally, the adoption of DES brought to light
some new etiological factors, including drug resistance or
local hypersensitivity reactions, which have also been asso-
ciated with DES failure (52,59).Table 1
Comparison of Principal Features of Restenotic Tissue
After Bare-Metal and Drug-Eluting Stent Implantation
Bare-Metal Stent
Restenosis
Drug-Eluting Stent
Restenosis
Imaging features
Angiographic
morphology
Diffuse pattern more
common
Focal pattern more
common
Optical coherence
tomography tissue
properties
Homogeneous, high-
signal band most
common
Layered structure or
heterogeneous most
common
Time course of late
luminal loss
Late loss maximal by
6–8 months
Ongoing late loss out
to 5 years
Histopathological features
Smooth muscle
cellularity
Rich Hypocellular
Proteoglycan content Moderate High
Peri-strut ﬁbrin and
inﬂammation
Occasional Frequent
Complete
endothelialization
3–6 months Up to 48 months
Thrombus present Occasional Occasional
Neoatherosclerosis Relatively infrequent,
late
Relatively frequent,
accelerated courseOther therapeutic considerations. Antiplatelet drugs
should be used before intervention for ISR, consistent with
recommendations after any coronary intervention. A 6- to
12-month duration of therapy has been recommended in
patients treated with DES or drug-coated balloons (DCB)
depending on the clinical presentation (60,61). Although in
some early studies, abciximab was considered to be of
particular value in patients with ISR, subsequent experience
failed to conﬁrm this clinical beneﬁt (62,63). Likewise, oral
sirolimus was initially considered to be of potential value in
patients with ISR (17). However, data supporting the long-
term efﬁcacy of this strategy are lacking, and the higher
incidence of adverse drug effects seen with this therapy in-
dicates that its use in the treatment of patients with ISR
cannot be recommended (64). Last, but not least, coronary
surgery should always be considered in patients with recal-
citrant ISR, particularly in those with a diffuse ISR pattern
or associated signiﬁcant disease in other major vessels (45).
However, the relatively scant information currently available
on the acute and long-term results of coronary surgery in
patients with ISR remains surprising. Most surgical series
describe good results in patients with previous interventions,
but dedicated studies focused on the results of coronary
surgery for patients with ISR remain very limited. Some
investigators suggest that saphenous vein grafts have an
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treated for ISR (65). To improve the long-term angio-
graphic and clinical results in these patients, the use of
arterial conduits should be always considered.
Role of Intravascular Imaging
Intracoronary imaging may play an important role in eval-
uation of underlying mechanical factors that contribute to
ISR (56,57). For example, intravascular ultrasound readily
detects the presence of neointimal hyperplasia obstructing
the stent, device underexpansion, or edge problems (56). In
addition, the external elastic lamina is usually well delineated
behind the stent struts, and this information provides
potentially valuable insights on vessel sizing for optimization
of stent expansion. However, due to its limited axial reso-
lution (150 mm), the lumen–neointimal interface may be
difﬁcult to delineate in some areas. In this respect, optical
coherence tomography (OCT) provides a much better axial
resolution (15 mm), yielding detailed images of the vessel–
lumen interface, the neointimal tissue, and the strut dis-
tribution (52,57). Against this setting, residual plaque
behind the stent is poorly visualized as a result of lower
tissue penetration compared with ultrasound. Moreover, inFigure 2 Patterns of In-Stent Restenosis as Depicted by Optical Coh
(A) Homogeneous bright neointimal proliferation. (B) Uniform neointimal proliferation wit
in the dark layer overlying the stent struts. (D) Multilayered pattern. *Wire artifact.patients with ISR, the detailed visualization of intrastent
tissue opens new avenues for tissue characterization (66) and
may permit establishment of new classiﬁcation systems for
ISR, potentially with important clinical implications.
ISR after BMS typically shows a homogeneous high-
signal tissue band according to OCT, which is character-
istic of neointimal hyperplasia rich in smooth muscle cells
(Fig. 2) (52). Alternatively, ISR after DES is typically
characterized by a layered or heterogeneous intrastent
tissue band. Such a tissue appearance may represent
hypocellular neointima with high proteoglycan or ﬁbrin
content or may be part of the spectrum of in-stent neo-
atherosclerotic changes. Indeed, some investigators sug-
gested that in patients with DES-ISR, OCT imaging may
exhibit presence of neoatherosclerotic tissue within the
stent in up to 50% of cases (67). Speciﬁc ﬁndings observed
include presence of neointimal disruptions, lipid-laden
neointima, lipid pools, thin-cap ﬁbroatheroma, and
macrophage accumulation. Notably, OCT allows not only
evaluation of the presence of neoatherosclerotic tissue per
se but also of the presence of unstable features (e.g., plaque
rupture, nonocclusive intracoronary thrombus), which may
play a strong role in prognostic assessment and clinical
decision making.erence Tomography
h microvessels (arrows). (C) Layered pattern with multiple microvessels (arrows)
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intravascular imaging is that it challenges the paradigm
that ISR and stent thrombosis are distinct pathological en-
tities. Recent studies suggest that in-stent neoatherosclerosis
may be identiﬁed as the underlying pathological substrate in a
substantial proportion of cases of both ISR and stent
thrombosis (40,67). Indeed, patients with complicated neo-
atherosclerosis may present as unstable angina or myocardial
infarction and a characteristic clinical picture of either ISR or
of very late stent thrombosis (Figs. 3 and 4) (68). Interest-
ingly, thrombus aspirates from patients with stent throm-
bosis frequently contain plaque remnants diagnostic of
neoatherosclerosis (69). These observations present evidence
to suggest that a continuous pathological spectrum of vessel
healing and disease recurrence or progression may underlie a
range of causes of late stent failure. ISR caused by severe
homogeneous smooth muscle cell proliferation represents
just one end of the spectrum. At the other extreme are pa-
tients experiencing stent thrombosis in a widely patent but
uncovered stent. In the middle, neoatherosclerosis manifests
clinically as a multifaceted and elusive condition causingFigure 3
OCT Images of a Patient Who Presented With Prolonged C
Everolimus-Eluting Stent in the Left Anterior Descending Co
Angiography demonstrated in-stent restenosis (ISR), but the patient developed a signiﬁcan
hyperplasia. (B) Bright neointima completely shadowing the stent struts (consistent with
with underlying cavities (D), together with large protruding red thrombi (T) causing major
Reproduced with permission from Alfonso F, Sandoval J. New insights on stent thrombos
Cardiol Intv 2012;5:141–4.both ISR and stent thrombosis (40,68). Hopefully, the
ongoing European Project PRESTIGE (Prevention of Late
Stent Thrombosis by an Interdisciplinary Global European
Effort) will provide new insights in this regard.
Conventional Balloon Angioplasty
Balloon angioplasty (BA) was one of the earliest strategies
used in patients experiencing ISR (70). The procedure is
technically straightforward and consistently associated with
satisfactory acute results and a very low incidence of com-
plications. Lumen enlargement results from both tissue
extrusion (axial and longitudinal) and additional stent
expansion (71). Results are particularly favorable in patients
with “focal” patterns of ISR (42). However, the long-term
results of patients with diffuse ISR are frequently shad-
owed by high recurrent restenosis rates. In patients with ISR
treated with BA, clinical predictors of recurrences are similar
to those seen in de novo lesions; in particular, patients with
diabetic status and those with early recurrences are at higher
risk (72). Although evidence supporting the value ofhest Pain 3 Years After the Implantation of an
ronary Artery
t enzymatic rise, diagnostic of a myocardial infarction. (A) Homogeneous neointimal
lipid-laden or inﬁltrated neointima). (C and D) Images of a ruptured thin cap (arrows)
distal shadowing of the stent. *Wire artifact. OCT ¼ optical coherence tomography.
is: in praise of large nationwide registries for rare cardiovascular events. J Am Coll
Figure 4
OCT Findings in a Patient Presenting With a Non–ST-Segment Elevation Myocardial Infarction 8 Years
After Treatment of a Lesion in the Left Circumﬂex Coronary Artery With a BMS
(A) Angiography disclosed focal in-stent restenosis with large thrombus (white arrow) within the stent (arrowheads). (B) OCT disclosed mild homogeneous neointimal
hyperplasia at the distal stent segment. (C) Proximally, a large, protruding red thrombus (T) was conﬁrmed. The proximal segments of the stent (D and E) showed ﬁndings
consistent with neoatherosclerosis: glistening neointima with attenuation (D), with a ruptured thin-cap ﬁbroatheroma (yellow arrow). *Wire artifact. Abbreviations as in
Figures 1 and 3. Reproduced with permission from Alfonso et al. (68).
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balloon size, or ﬁnal pressures) remains limited, most in-
vestigators try to optimize the results of the repeated pro-
cedures (45,59,72). In general, a balloon-to-artery ratio of
1.1:1 is selected. In the case of important underexpansion of
the underlying stent, high-pressure balloon dilation is used.
Of note, BA should target the narrowing rather than the
entire stented segment. Observed “dog bone” effects during
balloon dilation should promote a shift to aggressive di-
lations with a noncompliant balloon or occasionally with a
super-high-pressure noncompliant balloon (73). Actually,
some groups systematically use noncompliant balloons in
patients with ISR. A detailed review of the angiogram
showing the results of initial stent implantation provides
important technical clues to guide reinterventions (45). One
of the limitations of BA is that subacute tissue re-intrusion
back to the lumen tends to occur within minutes after the
last balloon inﬂation (23). This explains the “early lumen
loss” phenomenon detected in BA studies in this setting, a
ﬁnding also associated with subsequent recurrent restenosis.
Edge-related complications should be carefully avoided
during aggressive balloon dilations. Special care should be
paid to prevent balloon slippage outside the stent (“water-
melon seeding” phenomenon) (74). This problem, typical of
ISR lesions, occurs more often in severe and diffuse nar-
rowing, especially when balloons are oversized. This is not
just a time-consuming nuisance resulting in more cumber-
some procedures, but it is also associated with suboptimalacute results and adverse clinical and angiographic outcomes
that might be related to geographic miss. Occasionally,
despite dedicated maneuvers, anchoring the balloon at the
target site during inﬂation may be challenging. Some in-
vestigators propose the use of a buddy-wire technique to
stabilize the balloon (45). The use of progressive balloon
inﬂations and the selection of relatively small and short
balloons have also been advocated to prevent complications
should balloon slippage occur. Side branches emerging from
ISR lesions rarely cause problems during reinterventions.
These branches may experience clinically silent transient oc-
clusion, but they are systematically patent at late follow-up (75).
Available information supporting the value of BA in pa-
tients with DES-ISR is more limited than that obtained in
patients with BMS-ISR. Moreover, although a BA-alone
strategy has been frequently used in patients with ISR and
a high bleeding risk, the advent of DCB has rapidly gained
ground to become the dominant strategy in this patient cohort.
Cutting and Scoring Balloon Therapy
The cutting balloon is an attractive and simple technique for
treatment of patients with ISR. It offers protection against
the problems of “watermelon seeding.” The lateral blades of
this device anchor the balloon within the target lesion,
preventing balloon slippage–related problems. Moreover,
from a mechanistic standpoint, the device deeply incises
neointimal tissue and, at least theoretically, may favor its
JACC Vol. 63, No. 24, 2014 Alfonso et al.
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2665subsequent extrusion. Initial observational studies produced
promising results, clearly superior to those seen with con-
ventional BA (76). Results of a small randomized study
(25 patients per arm) suggested that cutting balloon therapy
was superior to BA in preventing early lumen deterioration
at 24 hours, and this ﬁnding was associated with a lower rate
of target lesion revascularization (12.5% vs. 40%) at late
follow-up (19). In RESCUT (Restenosis Cutting Balloon
Evaluation Trial), 428 patients with BMS-ISR were ran-
domized to receive either cutting BA or conventional BA
(20). At late follow-up, the angiographic restenosis rate,
minimal lumen diameter, and rates of clinical events were
similar in both arms. However, the occurrence of balloon
slippage was signiﬁcantly reduced (6.5% vs. 25%) in the
cutting balloon arm, and this ﬁnding seemed to be associ-
ated with a lower requirement for unplanned stent implan-
tation (Table 2). In a large observational study of patients
with ISR treated with gamma-brachytherapy, and in another
study using beta-brachytherapy, the beneﬁt of a systematic
use of the cutting balloon for lesion preparation could not be
demonstrated (77,78).
Scoring balloons are based on the same principle as cut-
ting balloons but are especially attractive in these patients
due to superior ﬂexibility and deliverability. Observational
studies suggest their value in selected cases with ISR (79).
The use of cutting or scoring balloons before DES or DCB
is potentially valuable, and this approach is being assessed in
ongoing randomized trials (e.g., ISAR-DESIRE 4 [Intra-
coronary Stenting and Angiographic Results: Optimizing
Treatment of Drug Eluting Stent In-Stent Restenosis 4;
NCT01632371]).
Debulking Techniques
The rationale for plaque debulking was based on the hy-
pothesis that removing the tissue obstructing a well-
expanded stent was the only action required to regain
vessel lumen. Intravascular ultrasound studies suggested that
lumen gain was larger and residual neointima smaller when
ablative techniques were used in patients with ISR compared
with use of standard therapies (80,81). Once again, early
observational studies suggested that the use of laser or
rotational atherectomy, followed by a “conservative” balloon
postdilation, was superior to conventional BA alone in these
patients. It was believed that after an adequate ablation, just
a gentle balloon postdilation was required to avoid additional
vessel wall injury potentially able to elicit a severe recurrent
proliferative response. Directional atherectomy was also used
in some small early studies, but this relatively bulky device
was soon abandoned because it was not well suited for small
or distal vessels, which are frequent locations of ISR (82).
Excimer laser showed good results in selected cases but
eventually proved to have poorer ablation capability
compared with rotational atherectomy (81).
The value of rotational atherectomy in patients with
BMS-ISR was analyzed in 2 randomized studies (Table 2).ROSTER (Randomized Trial of Rotational Atherectomy
Versus Balloon Angioplasty for Diffuse In-Stent Restenosis)
was a small single-center study in patients with diffuse ISR
in whom intravascular ultrasound was systematically used
to exclude cases with severe stent underexpansion (21).
In this trial, rotational atherectomy reduced the amount
of residual tissue within the stent and the rate of target le-
sion revascularization at follow-up, compared with BA
alone. Conversely, ARTIST (Angioplasty Versus Rotational
Atherectomy for Treatment of Diffuse In-Stent Restenosis
Trial), a larger multicenter randomized study (298 patients
with diffuse ISR) comparing rotational atherectomy with
BA alone, failed to show beneﬁt with rotational atherectomy
(14). In fact, the restenosis rate, as well as the rates of acute
complications and long-term clinical events, were higher in
the rotational atherectomy arm. Although some argued that
the low-pressure ﬁnal balloon inﬂations may have been
unable to effectively treat potentially underexpanded stents
(intravascular guidance was not mandated), the unfavorable
clinical and angiographic results of this large study eventually
led to abandonment of this form of therapy. However, in
rare cases, rotational atherectomy may still be required as a
bailout strategy in patients with undilatable ISR lesions as a
result of severely underexpanded stents (83,84) or calciﬁed
intrastent neoatherosclerosis (85). The value of ablative
techniques in patients with DES-ISR has not been
evaluated.
Vascular Brachytherapy
The treatment of patients with ISR represents the most suc-
cessful application of vascular brachytherapy. Brachytherapy
effectively suppressed the proliferative response and signiﬁ-
cantly reduced clinical and angiographic restenosis rates.
Randomized clinical trials in patients with ISR demonstrated
the superiority of brachytherapy compared with conventional
BA or atheroablative techniques (11–13,16,28) (Table 2).
Early balloons ﬁlled with radioactive ﬂuids showed experi-
mental promise but never demonstrated clinical efﬁcacy.
However, both beta and gamma radiation sources were able to
achieve major reductions in the angiographic restenosis rates.
Gamma emitters had profound tissue penetration, whereas
beta emitters had less tissue penetration. Radioprotection was
a major problem with gamma emitters; dosimetry problems
frequently arose with beta emitters.
Experience with brachytherapy provided many lessons
about the adverse effects of treatment with intracoronary
antiproliferative therapies. Indeed, the issues of geographic
miss and edge restenosis, as well as delayed arterial healing
and its sequelae (late stent thrombosis and late catch-up),
have been well described with this therapy (86). Intravas-
cular ultrasound provided important insights into many of
these complications, including documentation that late
thrombotic occlusion was often secondary to delayed endo-
thelization and vessel remodeling leading to late acquired
stent malapposition (87). These ﬁndings led to
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Table 2 Continued
First Author/Trial (Ref. #) Year Stent Therapy n
Age
(yrs)
DM
(%)
Length
(mm)
RVD
(mm)
MLD
(mm)
Angiographic Follow-Up Clinical Follow-Up
Time
(months)
RE
(%)
ISTLL
(mm)
ISGLL
(mm)
MLD
(mm)
DS
(%)
Time
(months)
MACE
(%)
Death
(%)
MI
(%)
TLR
(%)
TVR
(%)
Unverdorben et al. (29) 2009 DES-BMS DCB 66 65 33.3 15.7 2.85 0.74 6 4.0 0.19y 0.17y 2.08 29.4 12 7.6 1.5 0.0 6.3
DES 65 65 26.2 15.4 2.83 0.77 12.0 0.45 0.38 2.11 34.2 16.9 0.0 1.5 15.4
ISAR-DESIRE 2 (30) 2010 DES DES-P 225 67 38.8 12.5 2.75 0.95 6–8 21.0 0.38 0.25 2.16 25.4 12 19.6 4.5 1.8 13.8
DES-S 225 66 38.2 12.7 2.78 1.02 19.0 0.40 0.26 2.14 26.6 20.4 3.4 2.7 14.3
Habara et al. (31) 2011 DES DCB 25 70 56.0 12.7 2.69 0.99 6 9.0y 0.18y 0.17y 1.82 34.2 6 4.3y 0.0 0.0 4.3y
BA 25 69 68.0 13.2 2.90 0.92 63.0 0.72 0.72 1.28 58.0 41.7 0.0 0.0 41.7
Wiemer et al. (32) 2011 DES 44 65 49.0 25.2 2.89 0.70 6 4.0y 0.09y 2.66 7.78 12 4.0 2.0 0.0 2.0 2.0y
BT 47 64 49.0 17.2 2.77 0.85 23.0 0.39 1.75 36.9 27.0 2.0 6.0 16.0 19.0
PEPCAD (33) 2012 DES DCB 72 70 36.1 11.2 2.29 0.66 6 17.0y 0.43y 0.32y 1.75 29.6 6 16.7y 1.4 0.0 15.3y
BA 38 64 34.2 12.2 2.30 0.62 58.0 1.03 0.99 1.10 51.1 50.0 10.5 2.6 36.8
Song et al. (34) 2012 DES CB 48 62 31.2 7.5 2.93 0.80 9 21.0 0.30 0.25 2.08 16.5 12 6.3 0.0 0.0 6.3 6.3
DES-S 48 65 37.5 8.6 3.18 0.68 3.0 0.02y 0.06y 2.57 12.5 6.3 0.0 6.3 0.0 0.0
S-DES-d 32 61 25.0 22.2 3.19 0.94 5.0 0.13 0.13 2.58 25 9.6 3.1 3.1 3.1 3.1
E-DES-d 34 65 35.3 22.5 3.43 0.75 14.0 0.07y 0.07 2.71 18 8.8 2.9 2.9 5.8 5.8
CRYSTAL (35) 2012 DES DES-S 136 68 39.0 14.6 2.60 1.09 12 11.0 0.37 2.14y 21.0y 12 2.2 2.9 5.9 2.2
BA 61 67 38.0 13.4 2.50 1.58 14.0 0.41 1.71 29.8 1.6 1.6 13.1 0.0
ISAR-DESIRE 3 (36) 2013 DES DCB 137 68 41.0 2.75 0.97 6–8 27.0y 0.37 1.79 38 23.5 2.2 2.1 22.1 24.2
DES-P 131 69 47.0 2.80 0.93 24.0y 0.34 1.82 37.4 19.3 4.6 2.4 13.5 16.6
BA 134 67 37.0 2.72 0.88 57.0 0.70 1.26 54.1 46.2 5.3 1.5 43.5 45.1
Habara et al. (37) 2013 DES/BMS DCB 137 68 46.0 12.8 2.52 0.86 6 4.3y 0.11y 0.18y 1.87y 28.1y 6 6.6y 0.0 0.0 2.9y 6.6y
BA 71 70 42.0 13.7 2.49 0.84 31.9 0.49 0.72 1.42 44.1 31.0 0.0 0.0 31.0 31.0
RIBS V (38) 2014 BMS DCB 95 67 32.0 13.7 2.64 1.02 6 9.5 0.14 2.03 24 12 8.0 4.0 3.0 6.0 6.0
DES-E 94 64 20.0 13.8 2.64 0.93 4.7 0.04 2.44y 13y 6.0 0.0 4.0 1.0 2.0
PEPCAD-China (39) 2014 DES DCB 109 62 40.0 12.5 2.66 0.85 9 18.6 0.54 0.46 1.80 29 12 16.5 0.0 3.7 14.7 16.5
DES-P 106 62 33.0 13.8 2.72 0.86 23.8 0.62 0.55 1.76 31 16.0 2.0 6.6 10.4 16.0
Details of the literature search are given in the Methods. The primary endpoint of each trial is highlighted in bold. *Only 62% bare-metal stent (BMS)–in-stent restenosis (ISR). yp < 0.05.
ARTIST ¼ Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial; BA ¼ balloon angioplasty; BT ¼ intracoronary brachytherapy; CB ¼ cutting balloon; DCB ¼ drug-coated balloon; DES ¼ drug-eluting stent(s); DES-E ¼ everolimus drug-
eluting stent(s); DES-P ¼ paclitaxel drug-eluting stent(s); DES-S ¼ sirolimus drug-eluting stent(s); DM ¼ diabetes mellitus; E-DES-d ¼ everolimus-eluting stent for diffuse restenosis; ISAR-DESIRE ¼ Intracoronary Stenting or Angioplasty for Restenosis ReductiondDrug-Eluting
Stents for In-Stent Restenosis; ISAR-DESIRE 2 ¼ Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2); ISAR-DESIRE 3 ¼ Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 3; ISTLL ¼ in-stent
late loss; ISGLL ¼ in-segment late loss; LL ¼ lesion length; Long WRIST¼Washington Radiation for In-Stent Restenosis Trial for Long Lesions; MACE ¼major adverse cardiac events (including death or cardiac death, myocardial infarction [MI], and target lesion revascularization
[TLR] or target vessel revascularization [TVR] as considered in each trial for the combined outcome measure); MLD ¼minimal lumen diameter; OSIRIS ¼ Oral Sirolimus to Inhibit Recurrent In-stent Stenosis; PCI ¼ percutaneous coronary intervention (BA, rotational atherectomy
[RA], laser, BMS); RE ¼ binary restenosis; RIBS I ¼ Restenosis Intra-stent Balloon Angioplasty Versus Elective Stenting; RIBS II ¼ Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting; RIBS V ¼ Restenosis Intra-stent: Drug-eluting Balloon vs.
Everolimus-eluting Stent; ROSTER ¼ Randomized Trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-Stent Restenosis; ROTA ¼ rotational atherectomy; RVD ¼ reference vessel diameter; S-DES-d ¼ sirolimus-eluting stent for diffuse restenosis; SIR ¼ usual
dose oral sirolimus; SIRhd ¼ high-dose oral sirolimus; SISR ¼ Sirolimus-Eluting Stent vs. Brachytherapy in Patients With Bare Metal In-Stent Restenosis; TAXUS V ISR ¼ A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary
Stent in the Treatment of In-Stent Restenosis; WRIST ¼ Washington Radiation for In-Stent restenosis Trial.
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2668recommendations for extended durations of dual antiplatelet
therapy (61), mirroring many of the issues subsequently
encountered with ﬁrst-generation DES therapy.
In many respects, the advent of DES was the end of
brachytherapy. Two large randomized clinical trials
compared the efﬁcacy of brachytherapy versus DES in pa-
tients with BMS-ISR (Table 2). The SISR (Sirolimus-
Eluting Stent vs. Brachytherapy in Patients With Bare
Metal In-Stent Restenosis) trial allocated 384 patients with
BMS-ISR to undergo brachytherapy or sirolimus-eluting
stent implantation (26). At follow-up, the rates of target
vessel failure were 2-fold higher after brachytherapy. The
TAXUS V ISR (A Prospective, Randomized Trial Evalu-
ating Slow-Release Formulation TAXUS Paclitaxel-Eluting
Coronary Stent in the Treatment of In-Stent Restenosis)
trial randomized 396 patients with BMS-ISR to receive
either brachytherapy or paclitaxel-eluting stents (27). At
9-month follow-up, paclitaxel-eluting stents signiﬁcantly
reduced angiographic restenosis rates and the need for target
vessel revascularization. Subsequent reports from these 2
trials conﬁrmed that the advantage of DES over brachy-
therapy was maintained up to 5 years of follow-up.
In patients with DES-ISR, observational studies suggest
that brachytherapy was of clinical utility (88). However,
randomized trials against repeat DES or DCB therapy were
never conducted. Overall, the inherent complexity of the
technique, together with a reduced commercial interest, led
to the virtual abandonment of this strategy.Repeat Stenting for Patients With ISR
Bare-metal stents. Despite increasing vessel wall injury
and subsequent neointimal proliferation compared with BA
in de novo lesions, BMS reduce the risk of restenosis due
in large part to higher acute gain. In patients with BMS-
ISR, intravascular ultrasound studies also demonstrated
that repeat stenting was the best strategy to obtain a larger
acute lumen gain and better results immediately after the
procedure (80). In addition, mechanistic studies demon-
strated that the early lumen loss phenomenon seen after BA
was virtually abolished after repeat stenting (23). Such ob-
servations partially allayed the initial resistance from many
physicians to repeat stenting (the so-called “sandwich
technique”), although repeat stenting was initially reserved
for patients with suboptimal results or complications during
treatment of ISR (89,90).
The RIBS I (Restenosis Intra-stent Balloon Angioplasty
Versus Elective Stenting) trial randomized 450 patients with
BMS-ISR to receive either BA or repeat BMS implantation
(15). Acute angiographic results were signiﬁcantly better
after stent implantation due to a larger acute gain. However,
at 6-month follow-up, the late loss was also signiﬁcantly
larger in the stent group. As a result, ﬁnal minimal lumen
diameter and percent diameter stenosis were similar in both
arms. Likewise, recurrent restenosis rates were high and
similar in the 2 groups (15). Although this trial failed todemonstrate the beneﬁt of systematic BMS implantation in
patients with ISR, there was some evidence of clinical
beneﬁt in 2 relevant pre-speciﬁed lesion subsets. First, pa-
tients with large vessels (3 mm in diameter on quantitative
coronary angiography) obtained better long-term clinical
and angiographic outcomes after repeat stenting compared
with BA. Second, patients with ISR affecting the stent edge
and the adjacent vessel also exhibited better results after
stenting (91). Studies assessing the value of BMS in patients
with DES-ISR are lacking and unlikely to be undertaken.
Drug-eluting stents. The development of DES has revo-
lutionized the ﬁeld of interventional cardiology. In de novo
lesions, DES produce a profound inhibition of neointimal
proliferation (3–5). This characteristic is particularly attrac-
tive for patients with complex lesions and off-label in-
dications, including ISR. Early observational studies
suggested that ﬁrst-generation DES were very effective and
safe in patients with ISR and provided excellent clinical
outcomes (92). Although thorough lesion pre-dilation with
or without noncompliant balloons remains important to
treat potential underlying stent underexpansion (assuming
intravascular imaging is not performed), adjunctive DES
implantation offers durable preservation of acute gain. At
the same time, because stent fracture and mechanical issues
may be more prevalent in patients with DES-ISR than in
those with BMS-ISR, routine guidance with intracoronary
imaging is recommended by some (57). Finally, edge prob-
lems should be carefully prevented (as previously discussed).
The ISAR-DESIRE (Intracoronary Stenting or Angio-
plasty for Restenosis Reduction–Drug-Eluting Stents for
In-Stent Restenosis) trial was the ﬁrst randomized study
assessing the value of DES in patients with BMS-ISR (22)
(Table 2). In this 2-center German trial, 300 patients were
randomly allocated to treatment with sirolimus-DES,
paclitaxel-DES, or BA. The rate of recurrent restenosis
was signiﬁcantly reduced with sirolimus-DES (14.3%) and
paclitaxel-DES (21.7%) compared with BA (44.6%).
Patients treated with sirolimus-DES tended to have lower
rates of angiographic restenosis and target vessel revascu-
larization compared with those receiving paclitaxel-DES.
This treatment effect was also shown in a subsequent
meta-analysis comparing these 2 DES for BMS-ISR (93).
The RIBS II (Restenosis Intrastent: Balloon Angioplasty
Versus Elective Sirolimus-Eluting Stenting) trial was a
multicenter Spanish study that compared sirolimus-DES
versus BA in patients with BMS-ISR (25). Compared
with the BA arm, patients treated with sirolimus-DES had a
signiﬁcantly lower restenosis rate (11%) and superior long-
term clinical outcome, mainly as a result of a reduced need
for reinterventions (Fig. 5). Interestingly, the superiority of
sirolimus-DES over BA was consistent across 10 pre-
speciﬁed patient and lesion subsets. In addition, a mecha-
nistic intravascular ultrasound study conﬁrmed the dramatic
reduction of neointimal proliferation seen after use of
sirolimus-DES (25). The long-term (4-year) follow-up of this
study was reassuring, because a sustained clinical beneﬁt was
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2669demonstrated (94). Importantly, long-term adverse safety is-
sues have not been observed, at least with contemporary dual
antiplatelet treatment regimens.
Treatment of DES-ISR is especially challenging (1,10,59).
Overall, treatment of DES-ISR is associated with poorer late
outcomes than those obtained after treatment for BMS-ISR
(1,10,59). Although repeat stenting with DES was quickly
established as safe and effective, this problem persists even
when repeat stenting with DES is used. Initial observational
studies suggested that DES provided superior results com-
pared with other strategies such as BA or cutting balloon
angioplasty (95). Even in patients with focal patterns of DES-
ISR, repeat stenting with DES is superior to BA (1,59).
Repeat stenting with DES rapidly became established as
the treatment of choice in DES-ISR. However, the issue of
whether a DES eluting the same or a similar type of drug
(homo-DES approach) versus a switch to a different type of
drug (hetero-DES approach) should be selected has continued
to attract considerable debate (96). The beneﬁts of a switch
strategy are based on the hypothesis that it might overcome
drug resistance or speciﬁc polymer-related problems. Most
studies focused on assessing the relative value of different
drugs (mainly limus versus non-limus). Overall, results remain
inconclusive, and the evidence favoring a switch strategy is
weak. The ISAR-DESIRE 2 (Intracoronary Stenting and
Angiographic Results: Drug Eluting Stents for In-Stent
Restenosis 2) trial randomly allocated 450 patients with
sirolimus-DES-ISR to undergo repeat stenting with
sirolimus-DES versus switching to stenting with paclitaxel-
DES (30). Regarding antirestenotic efﬁcacy, there were noFigure 5 Diameter Stenosis at Follow-up in the RIBS II Study
BA ¼ balloon angioplasty; FU ¼ follow-up (broken lines); RE ¼ binary restenosis rate; RI
Sirolimus-Eluting Stenting; SES ¼ sirolimus-eluting stent(s). Modiﬁed with permission frodifferences between the 2 arms in late loss (0.40 vs. 0.38
mm), binary restenosis (19.6% vs. 20.6%), or target lesion
revascularization (16.6% vs. 14.6%). Safety was also com-
parable. These observations argue against a clear beneﬁt
from a switch DES strategy. However, it is important to
keep in mind that same-drug versus switch-drug is an
oversimpliﬁcation because the study DES differed
not just in drug but in many device components, which may
inﬂuence efﬁcacy.
In the RIBS III (Restenosis Intra-Stent: Balloon An-
gioplasty Versus Drug-Eluting Stent) trial, a prospective
multicenter registry including 363 patients with DES-ISR,
the use of a hetero-DES approach was recommended, and
outcomes were compared between patients who were treated
according to this recommendation versus those who were
not (97). The main ﬁnding was that the hetero-DES
approach (or switch DES strategy) was associated with
better clinical outcomes. Of note, the control group actually
included diverse therapeutic modalities, including BA,
BMS, and repeat stenting with a homo-DES approach.
However, when the results of the hetero-DES strategy were
compared directly with those of repeat stenting with a
homo-DES approach, the ﬁndings were broadly consistent.
Interestingly, in RIBS III, there was a suggestion that
the use of second-generation DES was superior to ﬁrst-
generation DES and also that guidance with intracoronary
imaging was associated with better long-term results.
Bioresorbable vascular scaffolds have also been proposed
as treatment for patients with ISR, although only anecdotal
cases of ISR treated with these devices have been reported toBS II ¼ Restenosis Intrastent: Balloon Angioplasty Versus Elective
m Alfonso et al. (25).
Figure 6
Comparative Efﬁcacy of DCB, DES, and BA
in the Treatment of Restenosis Within DES
Cumulative frequency distribution curves for percent diameter stenosis at 6- to
8-month angiographic surveillance in the ISAR-DESIRE 3 (Intracoronary Stenting and
Angiographic Results: Drug Eluting Stents for In-Stent Restenosis) randomized trial.
DCB ¼ drug-coated balloon; other abbreviations as in Figures 1 and 5. Reproduced
with permission from Byrne et al. (36).
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eventually disappear from the vessel wall, avoiding the
presence of multiple stent layers (“onion-skin” phenomena)
(99). Potential limitations of bioresorbable vascular scaffolds
in this setting include lumen crowding due to strut thickness
(particularly in small vessels), device ﬂexibility that may
affect access to restenotic lesions, and questions regarding
radial strength and recoil, which may be particularly
important in treating cases of ISR.
Finally, the best approach to patients presenting with
“recurrent” DES-ISR remains unsettled (99). Many of these
patients had resistant underexpandable stents despite the
use of high pressures. When severe resistant underexpansion
is conﬁrmed (which may require intracoronary imaging),
some investigators support the use of highly aggressive
strategies, including rotational atherectomy, to correct this
underlying problem (stent ablation). However, the risk/
beneﬁt of this approach remains unknown, and the problem
of publication bias (selective reporting of successful cases)
seems likely (83,84). In patients with recurrent ISR, im-
plantation of new DES would result in a vessel with multiple
metal layers (99). This patient cohort seems to be at a high
risk for additional recurrences, and coronary surgery should
always be contemplated for these “frequent ﬂyer” patients,
although this will usually be dictated by the prognostic
relevance of the restenotic lesion (45).
DCB Angioplasty
Although the value of DCB in de novo lesions remains
controversial, they have been proven to be very effective in
patients with both BMS-ISR and DES-ISR (100)
(Table 2). The pioneering study of Scheller et al. (24) in
52 patients with BMS-ISR demonstrated that DCB were
superior to BA alone. Six-month angiographic results were
signiﬁcantly improved in the DCB arm (late loss of 0.03 mm
vs. 0.74 mm; p < 0.002). The main limitation was thatthe control group therapy (BA) has now been superseded
by repeat stenting with DES. Accordingly, a subsequent
randomized trial by the same investigators compared
DCB with paclitaxel-DES in 130 patients with BMS-ISR
(29). At follow-up, DCB signiﬁcantly reduced the primary
endpoint of the study (angiographic late loss: 0.17 mm vs.
0.38 mm; p ¼ 0.03), although minimal lumen diameter and
diameter stenosis (more acceptable angiographic endpoints
in trials comparing balloons and stents) were similar in both
groups. Recently, the RIBS V (Restenosis Intra-stent:
Drug-eluting Balloon vs. Everolimus-eluting Stent) trial
reported the ﬁrst data from a randomized comparison of
DCB with second-generation everolimus-DES in 189 pa-
tients with BMS-ISR (38). In this study, the minimal lumen
diameter at follow-up was better after everolimus-DES
(2.01 mm vs. 2.36 mm; p < 0.001), although binary reste-
nosis (4.7% vs. 9.5%; p ¼ 0.22) and clinical events at 1 year
were low and similar in both groups. The study suggested
that second-generation DES exhibit some evidence of su-
periority in terms of angiographic endpoints but without a
clear signal of clinical beneﬁt. Therefore, additional studies
with a larger number of patients and a longer follow-up are
required to address this important question.
The value of DCB in patients with DES-ISR has also
been well tested (Table 2). Initially, a 50-patient, single-
center, randomized study demonstrated that in patients
with limus DES-ISR, DCB provided superior clinical and
angiographic results compared with BA (31). The angio-
graphic late loss was signiﬁcantly better in the DCB arm
(0.18 mm). The efﬁcacy of DCB in patients with DES-ISR
was subsequently conﬁrmed in a multicenter, randomized
trial including 110 patients with any type of DES-ISR (33).
Moreover, results of a controlled study suggested that DCB
are equivalent to paclitaxel-DES in patients with DES-ISR
(39). Interestingly, another randomized study suggested that
DCB are more effective in patients with BMS-ISR than in
those with DES-ISR (37), conﬁrming the consistent pattern
observed with all available therapeutic modalities. Recently,
the larger ISAR-DESIRE 3 (Intracoronary Stenting and
Angiographic Results: Drug Eluting Stents for In-Stent
Restenosis) multicenter randomized trial (36) investigated
the efﬁcacy of DCB versus paclitaxel-DES versus conven-
tional BA in patients with limus DES-ISR. The use of
these 3 arms is very interesting from an academic stand-
point, because BA provides the classical comparator,
whereas the 2 active arms used the same drug. This study
demonstrated that DCB were noninferior to paclitaxel-
DES and that both DCB and paclitaxel-DES were
superior to BA alone (Fig. 6). It was suggested that by
obviating the need of an additional stent layer, DCB might
emerge as the treatment strategy of choice for patients with
DES-ISR (36). In summary, data from the available ran-
domized clinical trials suggest that DCB are superior to
BA and similar to ﬁrst-generation DES in patients with
BMS-ISR or DES-ISR. This evidence is also supported
by some meta-analyses (101).
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a class effect for these devices cannot be assumed. A single
speciﬁc DCB using iopromide as a hydrophilic spacer was
used in all these trials. Further studies are required to conﬁrm
the efﬁcacy of different DCB technologies in this setting.
Long-term results of DCB seem to be largely maintained
over time (102). However, anecdotal reports suggest that
neoatherosclerosis may also occur in some patients treated
with DCB (103). In addition, whether DCB proves com-
parable to repeat stenting with a second-generation DES in
patients with DES-ISR remains unsettled. The ongoing
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents:
Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
randomized trial will address this issue. Finally, whether
the efﬁcacy of DCB can be further improved by lesion
preparation with a scoring or cutting balloon (104) remains
unknown and is the subject of the on-going ISAR-
DESIRE-4 randomized trial. Although largely speculative,
currently DCB may be preferred over DES in patients
with ISR and multiple metal layers, in those with large
side branches, and in those at high bleeding risk
undergoing prolonged dual antiplatelet therapy. Alterna-
tively, DES may be preferred over DCB in patients with
stent fracture or restenosis extending outside the stent edge
and also in patients with suboptimal results after lesion
predilation.
Conclusions
Although the advent of DES has reduced the incidence of
ISR, treatment of this clinical entity remains a prevailing
clinical problem. The substrate of ISR encompasses a
pathological spectrum ranging from smooth muscle cell
proliferation to neoatherosclerosis. Intracoronary imaging
provides unique insights into the underlying etiology of
ISR, but its role in optimizing the clinical results of these
reinterventions still remains unsettled. Evidence stemming
from controlled clinical studies suggests that among
currently available therapeutic modalities, DES and DCB
provide the best clinical and angiographic results in pa-
tients with ISR. However, the ﬁeld is rapidly evolving.
Further studies are required to identify clinical and
anatomic characteristics that may help to reﬁne selection
and tailor available therapeutic strategies to improve clin-
ical outcomes.
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